Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00116571 · ClinicalTrials.gov registry record · Phase 2
Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)
A Phase 2 study, sponsored by QLT.
- Terminated
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
NCT00116571: Clinical Trial Phase 2 study, sponsored by QLT.
NCT00116571 is a Phase 2 study that was terminated before completion, run by QLT. The registered enrollment target is 180 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00116571, a Phase 2 study, was terminated before completion, sponsored by QLT.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if transurethral photodynamic therapy with lemuteporfin has a therapeutic effect on lower urinary tract symptoms due to an enlarged prostate. Photodynamic therapy (known as "PDT") is a treatment that uses light to make a drug work. This means the drug is "light-activated". Light-activated drugs do not work until a certain color of light shines on the drug. When the drug and the light combine, they react together to destroy tissue. This study is investigating PDT with lemuteporfin as a possible treatment for an enlarged prostate. PDT with lemuteporfin may destroy overgrown prostate tissue and help urinary symptoms go back to normal.
Interventions
- DRUG Lemuteporfin for injection
- DEVICE Transurethral drug delivery system
- DEVICE Transurethral light delivery system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2005-05 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Why NCT00116571 stopped before completion
NCT00116571 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 3 interventions - of which Lemuteporfin for injection is the first listed.
NCT00116571 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00116571 about?
NCT00116571 is a clinical study titled "Photodynamic Therapy (PDT) for Lower Urinary Tract Symptoms (PLUS)". The purpose of this study is to determine if transurethral photodynamic therapy with lemuteporfin has a therapeutic effect on lower urinary tract symptoms due to an enlarged prostate. Photodynamic therapy (known as "PDT") is a treatment that uses light to make a drug work. This means the drug is "l...
What is the current status of trial NCT00116571?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2005-05. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00116571?
The interventions under investigation include: Lemuteporfin for injection (DRUG), Transurethral drug delivery system (DEVICE), Transurethral light delivery system (DEVICE).
Who is sponsoring clinical trial NCT00116571?
This trial is sponsored by QLT, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00116571's enrollment target sits among peer trials
180 365th of 2000 higher than 1,610 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia